# A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

> **NCT03033914** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 82 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** doxorubicin
- **DRUG:** Bleomycin
- **DRUG:** vinblastine
- **DRUG:** dacarbazine
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03033914
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-01-25
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03033914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03033914, "A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03033914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*